The sales are routine post-acquisition liquidity events, not a bearish signal. The CSO's sale was fully hedged by derivative exercises (zero net economic exposure change). Director grants are standard compensation. No follow-up action warranted, monitor next 10-Q for integration progress on Soleno's VYKAT XR.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 1 $160.48entry
- T+1 · 6mo ago −3.55%α −3.70% · $154.78
- T+5 · 5mo ago +2.12%α +4.87% · $163.88
- T+20 · 5mo ago +5.94%α +8.25% · $170.00
- T+60 · 3mo ago −4.79%α −5.76% · $152.80
Price Chart
How similar events traded
Executive Summary
Two Neurocrine executives sold shares totaling $2.32M in the week following the close of the $2.9B Soleno acquisition. The CSO's sale of $1.71M was paired with a derivative exercise, while the Chief Corp. Affairs Officer sold $609K. Director grants on May 27 are non-cash compensation and carry no economic signal. The sales represent ~0.015% of market cap, well below the 0.1% materiality threshold, and are likely liquidity-driven following the acquisition close.
Key Financial Metrics
Key Facts
- CSO Onyia Jude sold 11,000 shares at $155.53 for $1.71M on May 27, paired with derivative exercises (11,000 shares at $0 and 11,000 shares at $84.74)
- Chief Corp. Affairs Officer Boyer sold 3,888 shares at $156.64 for $609K on May 26
- Total open-market sales: $2.32M, representing ~0.015% of NBIX's $15.7B market cap
- 11 directors received non-cash stock grants on May 27 totaling ~29,000 shares at $0, routine compensation, no economic signal
- Sales occurred 9 days after the May 18 close of the $2.9B Soleno acquisition
Financial Impact
Total insider sales of $2.32M represent ~0.015% of market cap, immaterial relative to company size
Risk Factors
- Post-acquisition integration risk for Soleno's VYKAT XR (Prader-Willi syndrome) could pressure near-term earnings
- Additional $600M drawn on $1.0B credit facility increases leverage, though manageable for a $15.7B market cap company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1780092662734 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers